COMT (Val158Met) polymorphism is not associated to neuropathic pain in a Spanish population

被引:48
作者
Armero, P
Muriel, C
Santos, J
Sànchez-Montero, FJ
Rodríguez, RE
González-Sarmiento, R
机构
[1] Univ Salamanca, Dept Med, Unidad Med Mol, Salamanca 37007, Spain
[2] Univ Salamanca, Inst Neurociencias Castilla & Leon, Salamanca 37007, Spain
[3] Univ Salamanca, Serv Anestesia Hosp, Salamanca 37007, Spain
关键词
neuropathic pain; gene polymorphism; COMT; PCR;
D O I
10.1016/j.ejpain.2004.06.005
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
It is well known that the response to painful stimuli varies between individuals and this could be consequence of individual differences to pain sensitivity that may be related to genetic factors. Catechol-O-methyltransferase (COMT) is one of the enzymes that metabolize catecholamine neurotransmitters. Differences in the activity of COMT influence the functions of these neurotransmitters. A single nucleotide polymorphism (Val158Met) of COMT leads to a three to four fold reduction in the activity of the enzyme and has been associated to modifications in the response to a pain stressor. Neuropathic pain is a progressive nervous system disease due to an alteration of the peripheral or central nervous system. To elucidate the possible role of COMT polymorphism in the susceptibility to neuropathic pain, we have performed a case-control study in a Spanish population. Analysis of the (Val 158Met) COMT polymorphism was performed by PCR amplification and DNA digestion with restriction enzymes. Our study concludes that functional Val 158Met polymorphism of COMT gene is not associated to increased susceptibility to neuropathic pain. (c) 2004 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:229 / 232
页数:4
相关论文
共 27 条
[1]   Meta-analysis of the association between the catecholamine-O-methyl-transferase gene and obsessive-compulsive disorder [J].
Azzam, A ;
Mathews, CA .
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2003, 123B (01) :64-69
[2]   HUMAN LIVER CATECHOL-O-METHYLTRANSFERASE PHARMACOGENETICS [J].
BOUDIKOVA, B ;
SZUMLANSKI, C ;
MAIDAK, B ;
WEINSHILBOUM, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (04) :381-389
[3]   CONTINUOUS TREATMENT WITH THE D(2)-DOPAMINE RECEPTOR AGONIST QUINPIROLE DECREASES D(2)-DOPAMINE RECEPTORS, D(2)-DOPAMINE RECEPTOR MESSENGER-RNA AND PROENKEPHALIN MESSENGER-RNA, AND INCREASES MU-OPIOID RECEPTORS IN MOUSE STRIATUM [J].
CHEN, JF ;
ALOYO, VJ ;
WEISS, B .
NEUROSCIENCE, 1993, 54 (03) :669-680
[4]  
Erdal ME, 2001, MOL BRAIN RES, V94, P193
[5]   Update on the genetics of migraine [J].
Estevez, M ;
Gardner, KL .
HUMAN GENETICS, 2004, 114 (03) :225-235
[6]   MET-ENKEPHALIN CONCENTRATIONS IN STRIATUM RESPOND RECIPROCALLY TO ALTERATIONS IN DOPAMINE NEUROTRANSMISSION [J].
GEORGE, SR ;
KERTESZ, M .
PEPTIDES, 1987, 8 (03) :487-492
[7]   Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior [J].
Gogos, JA ;
Morgan, M ;
Luine, V ;
Santha, M ;
Ogawa, S ;
Pfaff, D ;
Karayiorgou, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (17) :9991-9996
[8]   Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease [J].
Goudreau, JL ;
Maraganore, DM ;
Farrer, MJ ;
Lesnick, TG ;
Singleton, AB ;
Bower, JH ;
Hardy, JA ;
Rocca, WA .
MOVEMENT DISORDERS, 2002, 17 (06) :1305-1311
[9]   Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis [J].
Indo, Y ;
Tsuruta, M ;
Hayashida, Y ;
Karim, MA ;
Ohta, K ;
Kawano, T ;
Mitsubuchi, H ;
Tonoki, H ;
Awaya, Y ;
Matsuda, I .
NATURE GENETICS, 1996, 13 (04) :485-488
[10]   Human catechol-O-methyltransferase down-regulation by estradiol [J].
Jiang, H ;
Xie, T ;
Ramsden, DB ;
Ho, SL .
NEUROPHARMACOLOGY, 2003, 45 (07) :1011-1018